XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
REVENUE
9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard, Oncotype®, and COVID-19 tests. The services are completed upon release of a patient’s test result to the ordering healthcare provider.
Disaggregation of Revenue
The following table presents the Company’s revenues disaggregated by revenue source:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2022202120222021
Screening
Medicare Parts B & C$140,366 $116,088 $389,373 $329,034 
Commercial188,923 151,245 531,789 419,268 
Other31,470 13,045 100,013 36,341 
Total Screening360,759 280,378 1,021,175 784,643 
Precision Oncology
Medicare Parts B & C$47,038 $51,607 $152,224 $144,753 
Commercial42,660 42,844 134,658 136,800 
International31,533 27,229 89,536 80,133 
Other30,212 23,732 81,640 50,942 
Total Precision Oncology151,443 145,412 458,058 412,628 
COVID-19 Testing$10,871 $30,589 $52,051 $96,004 
Total$523,073 $456,379 $1,531,284 $1,293,275 
Screening revenue primarily includes laboratory service revenue from Cologuard and PreventionGenetics LLC (“PreventionGenetics”) tests while Precision Oncology revenue includes laboratory service revenue from global Oncotype products and therapy selection products, including OncomapTM and Oncomap ExTraTM.
At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. The Company recognized revenue from a change in transaction price of $6.4 million and $17.6 million for the three and nine months ended September 30, 2022, respectively. The Company recorded a downward adjustment to revenue from a change in transaction price of $0.2 million and $13.2 million for the three and nine months ended September 30, 2021, respectively.
The Company had deferred revenue of $2.3 million and $1.0 million as of September 30, 2022 and December 31, 2021, respectively. Deferred revenue is reported in other current liabilities in the Company’s condensed consolidated balance sheets.
Revenue recognized for the three months and nine months ended September 30, 2022, which was included in the deferred revenue balance at the beginning of each period, was not significant. Revenue recognized for the three months and nine months ended September 30, 2021, which was included in the deferred revenue balance at the beginning of each period, was $0.2 million and $24.6 million, respectively. Of the $24.6 million of revenue recognized for the nine months ended September 30, 2021, $24.3 million related to COVID-19 testing.